subject area of
- A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer Academic Article
- Chemosensitization of gemcitabine-resistant human bladder cancer cell line bothin vitroandin vivousing antisense oligonucleotide targeting the anti-apoptotic gene, clusterin Academic Article
- Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy Academic Article
- Low Density Lipoprotein Receptor-Related Protein-2 Expression in Efferent Duct and Epididymal Epithelia: Evidence in Rats for its in Vivo Role in Endocytosis of Apolipoprotein J/Clusterin1 Academic Article
- Phase II Trial of OGX-011 in Combination with Docetaxel in Metastatic Breast Cancer Academic Article
- Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer Conference Paper
- Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c Academic Article
- Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration‐resistant prostate cancer treated with custirsen Academic Article
- Serum Immune-Related Proteins are Differentially Expressed during Hibernation in the American Black Bear Academic Article
- Stressproteine bei der Pathogenese des Prostatakarzinoms Academic Article
- Sulfated glycoprotein-2 synthesized by nonciliated cells of the efferent ducts is targeted to the lysosomal compartment Academic Article
- Targeting of endogenous sulfated glycoprotein-1 and -2 to lysosomes within nonciliated cells of the efferent ducts during postnatal development of the rat Academic Article